Delving into the Latest Updates on Gasherbrum Bio, Inc. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

GLP-1R(胰高血糖素样肽-1受体)	1

关联

1

项与 Gasherbrum Bio, Inc. 相关的药物

Aleniglipron

靶点

GLP-1R

作用机制

GLP-1R激动剂

在研机构

硕迪生物 [+1]

原研机构

Gasherbrum Bio, Inc.

在研适应症

肥胖 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

5

项与 Gasherbrum Bio, Inc. 相关的临床试验

NCT06703021

/ Recruiting临床2期

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Efficacy of Increasing Optimal Doses of GSBR-1290 in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity (ACCESS II)

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various GSBR-1290 dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 36-week period.

开始日期2024-12-20

申办/合作机构

Gasherbrum Bio, Inc.

NCT06693843

/ Recruiting临床2期

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of GSBR-1290 in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity

This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of GSBR-1290 in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to GSBR-1290 or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of GSBR-1290 or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment.

开始日期2024-10-17

申办/合作机构

Gasherbrum Bio, Inc.

NCT06139055

/ Active, not recruiting临床1期

A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.

开始日期2023-10-02

申办/合作机构

Gasherbrum Bio, Inc.

100 项与 Gasherbrum Bio, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Gasherbrum Bio, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Gasherbrum Bio, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Gasherbrum Bio, Inc. 相关的转化医学

登录后查看更多信息